Literature DB >> 8656905

Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group.

A D Sadovnick1, G C Ebers, D A Dyment, N J Risch.   

Abstract

BACKGROUND Increased familial risks in multiple sclerosis (MS) range from 300-fold for monozygotic twins to 20-40-fold for biological first-degree relatives, suggesting a genetic influence. Yet if one identical twin has MS the other usually will not. One way of sorting out the contributions of genes and environment is to study half-sibs. METHODS In a Canadian population-based sample of 16 000 MS cases seen at 14 regional MS clinics one half-sib (or more) was reported by 939 index cases. By interview we elicited information on family structure and an illness in half-sibs and any full brothers or sisters. FINDINGS The age-adjusted MS rate in the 1839 half-sibs of these index cases was 1.32 percent compared with 3.46 percent for the 1395 full sibs of the same cases (p<0.001; likelihood ratio test). There were no significant differences in risk for maternal versus paternal half-sibs (1.42 percent vs 1.19 percent) or for those raised together versus those raised apart from the index case (1.17 percent vs 1.47 percent). INTERPRETATION Besides demonstrating the power and the feasibility of using half-sib studies to throw light on the aetiology of complex disorders, our findings show that a shared environment does not account for familial risk in MS and that maternal effects (such as intrauterine and perinatal factors, breastfeeding, and genomic imprinting) have no demonstrable effect on familial risk. Halving the number of potentially contributory genes (by comparing full-sib and half-sib rates) lowers the risk of MS by a factor of 2.62, an observation consistent with a polygenic hypothesis.

Entities:  

Mesh:

Year:  1996        PMID: 8656905     DOI: 10.1016/s0140-6736(96)90807-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  67 in total

Review 1.  The genetic epidemiology of multiple sclerosis.

Authors:  A Compston
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

Review 2.  Genetic analysis of multiple sclerosis.

Authors:  Alastair Compston; Stephen Sawcer
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

3.  Twin concordance and sibling recurrence rates in multiple sclerosis.

Authors:  C J Willer; D A Dyment; N J Risch; A D Sadovnick; G C Ebers
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

Review 4.  Stem cell transplantation in multiple sclerosis: current status and future prospects.

Authors:  Gianvito Martino; Robin J M Franklin; Anne Baron Van Evercooren; Douglas A Kerr
Journal:  Nat Rev Neurol       Date:  2010-04-20       Impact factor: 42.937

Review 5.  Multiple sclerosis genetics--is the glass half full, or half empty?

Authors:  Jorge R Oksenberg; Sergio E Baranzini
Journal:  Nat Rev Neurol       Date:  2010-07-13       Impact factor: 42.937

6.  Thomas John (Jock) Murray, OC, MD, FRCP(C), MACP, LLD(HON), DSc(Hon), FRCP(Lon): a conversation with the editor. Interview by William Clifford Roberts.

Authors:  Thomas John Murray
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-10

7.  Definition of a 1.06-Mb region linked to neuroinflammation in humans, rats and mice.

Authors:  Johan Ockinger; Pablo Serrano-Fernández; Steffen Möller; Saleh M Ibrahim; Tomas Olsson; Maja Jagodic
Journal:  Genetics       Date:  2006-04-19       Impact factor: 4.562

8.  Eae19, a new locus on rat chromosome 15 regulating experimental autoimmune encephalomyelitis.

Authors:  Jian Rong Sheng; Maja Jagodic; Ingrid Dahlman; Kristina Becanovic; Rita Nohra; Monica Marta; Ellen Iacobaeus; Tomas Olsson; Erik Wallström
Journal:  Genetics       Date:  2005-02-16       Impact factor: 4.562

9.  Investigation of seven proposed regions of linkage in multiple sclerosis: an American and French collaborative study.

Authors:  Margaret A Pericak-Vance; Jackie B Rimmler; Jonathan L Haines; Melissa E Garcia; Jorge R Oksenberg; Lisa F Barcellos; Robin Lincoln; Stephen L Hauser; Isabelle Cournu-Rebeix; Ariele Azoulay-Cayla; Olivier Lyon-Caen; Bertrand Fontaine; Emmanuelle Duhamel; Helene Coppin; David Brassat; Marie-Paule Roth; Michel Clanet; Mehdi Alizadeh; Jacqueline Yaouanq; Erwann Quelvennec; Gilbert Semana; Gilles Edan; Marie-Claude Babron; Emmanuelle Genin; Francoise Clerget-Darpoux
Journal:  Neurogenetics       Date:  2003-11-01       Impact factor: 2.660

Review 10.  Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs.

Authors:  Christine Lebrun; Fanny Rocher
Journal:  CNS Drugs       Date:  2018-10       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.